India, March 23 -- Advances in cancer research are improving how doctors diagnose and monitor diseases. One emerging tool is ...
FDA fast track designation supports development of pelareorep plus bevacizumab/FOLFIRI in 2L KRAS-mutant MSS mCRC, enabling more frequent regulatory engagement and potential accelerated pathways.
Doncaster and Bassetlaw Teaching Hospitals (DBTH) has embedded a dedicated role to help patients navigate the often ...